The blood irradiator researched and developed by the Nuclear Power Institute of China (NPIC) of the China National Nuclear Corporation (CNNC) was recently issued a registration certificate by the China Food and Drug Administration (CFDA), giving it official approval for marketing.

This is a remarkable achievement for CNNC in the nuclear medical facility field, enriching and upgrading the company’s industrial layout.

Blood radiation has been an effective method for avoiding fatal blood transfusion complications. Performance evaluations of NPIC’s product show that it has reached an advanced international level and has significant market potential arising from its professional design, effectiveness in making blood transfusion safer through avoiding complications and maintaining other cellular functions, and wide application in the fields of biological material evaluation, cell culturing, blood testing, animal experimentation, and electron component irradiation research.

A blood irradiator is a clinical device for blood radiation treatment. It is concerned with blood transfusion safety, radiation safety and equipment electrical safety, and is thus among the most strictly managed devices in medical facilities. All of its R&D process must meet national standards and go through precise detection tests, clinical trials and registration evaluation before entering the market. 

NPIC invented its first blood irradiator at the end of 2006 and passed the final technological review by the CFDA in early 2016 resulting in the product registration certificate.